Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights
Oncolytics Biotech (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapy oncology company, has scheduled a conference call and webcast for Wednesday, May 14, 2025, at 4:30 p.m. ET. The event will provide a corporate update and discuss financial results for the first quarter of 2025.
Participants can join through North American toll-free number (888) 510-2154 or international line (437) 900-0527, using conference ID 28038. A webcast replay will be available on the company's Investor Relations page for three months, while a dial-in replay will be accessible for one week using (888) 660-6345 (North America) or (289) 819-1450 (International) with replay code 28038#.
Oncolytics Biotech (NASDAQ: ONCY) (TSX: ONC), un'azienda di immunoterapia oncologica in fase clinica, ha programmato una conference call e webcast per mercoledì 14 maggio 2025 alle 16:30 ET. L'evento fornirà un aggiornamento aziendale e discuterà i risultati finanziari del primo trimestre 2025.
I partecipanti possono collegarsi tramite il numero verde nordamericano (888) 510-2154 o la linea internazionale (437) 900-0527, utilizzando l'ID conferenza 28038. Una replica del webcast sarà disponibile sulla pagina Relazioni con gli Investitori dell'azienda per tre mesi, mentre la replica telefonica sarà accessibile per una settimana chiamando (888) 660-6345 (Nord America) o (289) 819-1450 (Internazionale) con il codice replay 28038#.
Oncolytics Biotech (NASDAQ: ONCY) (TSX: ONC), una empresa de inmunoterapia oncológica en etapa clínica, ha programado una llamada de conferencia y un webcast para el miércoles 14 de mayo de 2025 a las 4:30 p.m. ET. El evento ofrecerá una actualización corporativa y discutirá los resultados financieros del primer trimestre de 2025.
Los participantes pueden unirse a través del número gratuito en Norteamérica (888) 510-2154 o la línea internacional (437) 900-0527, usando el ID de conferencia 28038. La repetición del webcast estará disponible en la página de Relaciones con Inversionistas de la empresa durante tres meses, mientras que la repetición por llamada estará accesible por una semana usando (888) 660-6345 (Norteamérica) o (289) 819-1450 (Internacional) con el código de repetición 28038#.
Oncolytics Biotech (NASDAQ: ONCY) (TSX: ONC), 임상 단계 면역항암제 회사는 2025년 5월 14일 수요일 오후 4시 30분(동부시간)에 컨퍼런스 콜과 웹캐스트를 예정하고 있습니다. 이번 행사는 회사 업데이트와 2025년 1분기 재무 결과를 발표할 예정입니다.
참석자는 북미 무료 전화번호 (888) 510-2154 또는 국제 전화 (437) 900-0527로 접속 가능하며, 컨퍼런스 ID는 28038입니다. 웹캐스트 재방송은 회사 투자자 관계 페이지에서 3개월간 제공되며, 전화 재방송은 (888) 660-6345(북미) 또는 (289) 819-1450(국제) 번호로 1주일간 재생 코드 28038#를 사용해 들을 수 있습니다.
Oncolytics Biotech (NASDAQ : ONCY) (TSX : ONC), une société d'immunothérapie oncologique en phase clinique, a programmé une conférence téléphonique et un webcast pour le mercredi 14 mai 2025 à 16h30 ET. Cet événement fournira une mise à jour d'entreprise et discutera des résultats financiers du premier trimestre 2025.
Les participants peuvent se joindre via le numéro sans frais nord-américain (888) 510-2154 ou la ligne internationale (437) 900-0527, en utilisant l'ID de conférence 28038. Une rediffusion du webcast sera disponible sur la page Relations Investisseurs de la société pendant trois mois, tandis qu'une rediffusion téléphonique sera accessible pendant une semaine en composant le (888) 660-6345 (Amérique du Nord) ou le (289) 819-1450 (International) avec le code de rediffusion 28038#.
Oncolytics Biotech (NASDAQ: ONCY) (TSX: ONC), ein klinisch tätiges Immuntherapie-Onkologieunternehmen, hat eine Telefonkonferenz und einen Webcast für Mittwoch, den 14. Mai 2025, um 16:30 Uhr ET angesetzt. Die Veranstaltung bietet ein Unternehmensupdate und bespricht die Finanzergebnisse für das erste Quartal 2025.
Teilnehmer können über die nordamerikanische gebührenfreie Nummer (888) 510-2154 oder die internationale Leitung (437) 900-0527 mit der Konferenz-ID 28038 teilnehmen. Eine Webcast-Wiederholung ist für drei Monate auf der Investor-Relations-Seite des Unternehmens verfügbar, während eine Telefon-Wiederholung für eine Woche unter (888) 660-6345 (Nordamerika) oder (289) 819-1450 (International) mit dem Wiedergabecode 28038# abrufbar ist.
- None.
- None.
Conference call and webcast to take place on Wednesday, May 14, 2025, at 4:30 p.m. ET
Conference Call & Webcast
Date: Wednesday, May 14, 2025
Time: 4:30 p.m. ET
Dial In – North American Toll-Free: (888) 510-2154
Dial In – International: (437) 900-0527
RapidConnect: to join the conference call without operator assistance, please click here
Conference ID (if needed): 28038
Webcast: please click here
A webcast of the call will also be available on the Investor Relations page of Oncolytics' website, available by clicking here, and will be archived for three months. A dial-in replay will be available for one week and can be accessed by dialing (888) 660-6345 (
About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid and hematological malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For further information, please visit: www.oncolyticsbiotech.com or follow the company on social media on LinkedIn and on X @oncolytics.
Company Contact
Jon Patton
Director of IR & Communication
jpatton@oncolytics.ca
Investor Relations for Oncolytics
Mike Moyer
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com
Media Contact for Oncolytics
Michael Rubenstein
LifeSci Communications
mrubenstein@lifescicomms.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/oncolytics-biotech-to-host-conference-call-to-discuss-first-quarter-financial-results-and-recent-operational-highlights-302446465.html
SOURCE Oncolytics Biotech® Inc.
FAQ
When is Oncolytics Biotech (ONCY) Q1 2025 earnings call?
How can I access Oncolytics Biotech's (ONCY) Q1 2025 earnings call?
How long will Oncolytics Biotech's (ONCY) Q1 2025 earnings call replay be available?
What is the replay information for Oncolytics Biotech's (ONCY) Q1 2025 earnings call?
